Pipeline · Bill → Law
Step 1
Introduced
Jun 7, 2023
Step 2
Referred
Jun 9, 2023
E&C · HELP
Step 3
Committee
Jul 19, 2023
Reported out
Step 4
House floor
Step 5
Senate
Sep 24, 2024
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary
This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)
Timeline · 15 actions
Sep 24, 2024
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sep 23, 2024
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Sep 23, 2024
Considered under suspension of the rules.
Sep 23, 2024
DEBATE - The House proceeded with forty minutes of debate on H.R. 3884.
Sep 23, 2024
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Sep 23, 2024
Motion to reconsider laid on the table Agreed to without objection.
Aug 25, 2023
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-166.
Aug 25, 2023
Placed on the Union Calendar, Calendar No. 132.
Jul 19, 2023
Committee Consideration and Mark-up Session Held.
Jul 19, 2023
Ordered to be Reported (Amended) by the Yeas and Nays: 50 - 0.
Jul 13, 2023
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 28 - 0.
Jul 13, 2023
Subcommittee Consideration and Mark-up Session Held
Jun 9, 2023
Referred to the Subcommittee on Health.
Jun 7, 2023
Introduced in House
Jun 7, 2023
Referred to the House Committee on Energy and Commerce.